Osimertinib (Tagrix) is the 1st and only drug of its kind approved by USFDA for the treatment of epidermal growth factor receptor (EGFR) positive Non- Small Cell Lung Cancer (NSCLC) patient with T790M mutation.

Therapeutic indications

TAGRIX is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

Product Name        : Tagrix

Generic Name        : Osimertinib
Formulation         : Tablet

Available Pack size : 30’s

Strengths           : 40mg & 80mg

Website : www.tagrix.net